Pliant Therapeutics

$36.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.05 (+2.96%) As of 5:36 PM UTC today

Why Robinhood?

You can buy or sell PLRX and other stocks, options, and ETFs commission-free!

About PLRX

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. The listed name for PLRX is Pliant Therapeutics, Inc. Common Stock.

CEO
Bernard Coulie
Employees
62
Headquarters
South San Francisco, California
Founded
2015
Market Cap
1.55B
Price-Earnings Ratio
Dividend Yield
Average Volume
218.46K
High Today
$38.98
Low Today
$34.51
Open Price
$34.88
Volume
81.94K
52 Week High
$43.92
52 Week Low
$19.43

PLRX Earnings

-$1.39
-$0.93
-$0.46
$0.00
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like

DCRB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure